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Abstract
High-mobility group box protein 1 (HMGB1) is a non-histone
nuclear protein that has a dual function. Inside the cell, HMGB1
binds DNA, regulating transcription and determining chromosomal
architecture. Outside the cell, HMGB1 can serve as an alarmin to
activate the innate system and mediate a wide range of physio-
logical and pathological responses. To function as an alarmin,
HMGB1 translocates from the nucleus of the cell to the extra-
cellular milieu, a process that can take place with cell activation as
well as cell death. HMGB1 can interact with receptors that include
RAGE (receptor for advanced glycation endproducts) as well as
Toll-like receptor-2 (TLR-2) and TLR-4 and function in a synergistic
fashion with other proinflammatory mediators to induce responses.
As shown in studies on patients as well as animal models, HMGB1
can play an important role in the pathogenesis of rheumatic
disease, including rheumatoid arthritis, systemic lupus erythe-
matosus, and polymyositis among others. New approaches to
therapy for these diseases may involve strategies to inhibit
HMGB1 release from cells, its interaction with receptors, and
downstream signaling.
Introduction
High-mobility group box protein 1 (HMGB1) is a highly con-
served nuclear protein that is a prototype for a unique class
of proinflammatory mediators called alarmins. As a group,
alarmins display distinct intracellular and extracellular
activities, with potent stimulation of the innate immune system
as their cardinal feature. While the intracellular functions of
alarmins vary, in their extracellular form, they function as pro-
inflammatory mediators to alert the immune system to tissue
damage and to trigger an immediate response. A key facet of
the biology of alarmins is therefore their translocation from
the inside to the outside of the cell [1].
During the past decade, studies in both patients and animal
models have established the alarmin activity of HMGB1 in
acute and chronic inflammatory conditions, including the
rheumatic diseases. Since HMGB1 may be a target of new
therapy, HMGB1 biology has emerged as a rapidly expanding
field of both basic and clinical research. This review will
summarize the role of HMGB1 in the pathogenesis of the
rheumatic diseases and its potential as a therapeutic target.
Concept of an alarmin
Mammalian organisms have evolved diverse systems to
recognize certain molecules as ‘danger signals’ and respond
quickly to life-threatening events, including infection and
trauma. These danger signals can arise from exogenous as
well as endogenous sources and can induce innate and
adaptive immune responses. Exogenous danger signals from
microorganisms are also called PAMPs (pathogen-associated
molecular patterns) whereas endogenous danger molecules
are also called DAMPs (damage-associated molecular
patterns), reflecting their respective origins [2].
Among endogenous danger molecules, alarmins differ in
biochemical structure and interact with a variety of receptor
systems, including the Toll-like receptors (TLRs). Irrespective
of their structure or intracellular location, alarmins share the
following features: (a) rapid release from cells in response to
infection or tissue damage, (b) chemoattraction and activa-
tion of antigen-presenting cells, and (c) activation of innate
and adaptive immunity. HMGB1 is probably the best-
characterized alarmin. Other examples are the defensins and
eosinophil-derived neurotoxin.
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Structure of HMGB1
HMGB1 was first discovered as a nuclear protein with rapid
migration in electrophoretic gels, a property leading to its
name. HMGB1 is a member of the high-mobility group
(HMG) protein superfamily, whose members are abundant
and ubiquitous nuclear proteins. HMGB1 is found in all
mammalian tissues and is highly conserved among various
species. As shown in biochemical studies, HMGB1 is a
single polypeptide chain of 215 amino acids in length and is
organized into two DNA-binding regions (termed the A box
and B box) and an acidic tail [3,4].
While primarily nuclear, HMGB1 can be present in the cyto-
plasm as well as the surface of certain cells. Thus, Rauvala
and colleagues [5] identified a surface protein that promotes
neurite outgrowth. Originally called p30, this protein was
renamed amphoterin because of its content of both acidic
and basic residue segments. The sequence for amphoterin
matches the sequence of HMGB1, establishing HMGB1 as a
membrane protein on certain cells [5,6].
HMGB1 binds DNA as well as nucleosomes and plays an
important structural role, modifying chromosomal architecture
and regulating transcription. HMGB1 has a preference for
certain DNA conformations and sequences, with a particular
predilection for DNA with distorted structures such as bends.
HMGB1 readily circulates in the nucleus and may contribute
to transcriptional regulation by altering chromatin structure as
well as interacting with transcription factors to promote their
binding with DNA [7]. While the precise nuclear function of
HMGB1 is being elucidated, the absence of this protein is
postnatally lethal, with newborn knockout mice succumbing
to hypoglycemia.
Assay of HMGB1
Although HMGB1 has immunostimulatory activities, its assay
differs from that of conventional cytokines which can be
measured by either enzyme-linked immunosorbent assays
(ELISAs) or functional assays. Indeed, most studies on the
expression of HMGB1 have used Western blot assays.
Furthermore, because an important determinant of the activity
of HMGB1 is its location, microscopy is valuable for defining
not only the presence of HMGB1 in a specimen but its
disposition inside the cell (nuclear or cytoplasm) and outside
the cell. ELISAs for the measurement of HMGB1 have also
been described but their use has been limited by interference
from other material in biological specimens. In contrast, a cell-
based ELISA (enzyme-linked immunosorbent spot, or ELISPOT)
to detect individual cells secreting HMGB1 can reliably
measure such cells in cultures and provides a useful
alternative to Western blotting [8,9].
Cytokine activity of HMGB1
The discovery of HMGB1 as an alarmin resulted from efforts
to identify mediators of sepsis by characterizing novel
proteins produced by macrophages. Using this approach,
Wang and colleagues [10] showed that HMGB1 is released
from macrophages stimulated in vitro with lipopolysaccharide
(LPS) and, furthermore, that HMGB1 can mediate sepsis in
experimental models. Following this seminal report, Scaffidi
and colleagues [11] and Rovere-Querini and colleagues [12]
showed that HMGB1 can be released from necrotic cells and
can stimulate necrosis-induced inflammation. Together, these
studies established the alarmin activity of HMGB1 and its
extracellular translocation in the settings of immune cell
activation and cell death.
In its role as an alarmin, HMGB1 displays a wide range of
immunological effects that resemble those of LPS itself and
other cytokines such as tumor necrosis factor (TNF)-α. In
addition to its effects on hematopoietic cells, HMGB1 may
play an important reparative as well as pathogenetic role in
angiogenesis, myogenesis, and skeletal muscle function
[13-30]. These activities have been demonstrated in vitro and
in vivo, with effects of inhibitors (for example, antibodies)
demonstrating their biological relevance in disease settings
(these activities are summarized in Table 1).
HMGB1 in adaptive immunity
Dendritic cells (DCs) both secrete and respond to HMGB1.
The protein activates DCs and induces a functional matura-
tion, including enhanced expression of CD80, CD83, and
CD86 and MHC (major histocompatibility complex) class II
antigens. Furthermore, maturing DCs need HMGB1 for
proper migration to lymph nodes. HMGB1 enables prolifera-
tion and polarization of naive CD4 T lymphocytes toward a T-
helper 1 phenotype and acts as an adjuvant in vivo to
enhance antigen-induced IgG production [17,19,28,29]. The
exploration of functional roles of HMGB1 in adaptive
immunity has just started and has been summarized by
Bianchi and Manfredi [29] in a recent review.
Mode of action
The mechanism by which HMGB1 acts, while originally
appearing to be straightforward, has been increasingly diffi-
cult to define. Thus, original studies posited that HMGB1
functions as a cytokine to trigger responses via interaction by
receptors used by other danger molecules such as TLR
ligands. In these studies, three molecules emerged as
candidates for the relevant receptor: TLR-2, TLR-4, and the
receptor for advanced glycation endproducts (RAGE)
[31-33]. The triggering of three different receptors was
surprising, although it could reflect the biochemical
properties of HMGB1, including its charged structure and its
ability to bind multiple protein sequences [34].
Complicating the interpretation of signaling by HMGB1, there
is evidence furthermore that, depending on the source, highly
purified HMGB1 may not itself be active [35-37]. Rather than
a vagary in preparation or lability in the active moiety, how-
ever, these findings could point to a fundamental aspect of
HMGB1’s stimulatory activity. Thus, for full activity, HMGB1Page 3 of 10
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may need to form a complex with another component to
activate inflammation by enhancing effects stimulated by a
PAMP, a DAMP, or a proinflammatory cytokine. Importantly,
HMGB1 can bind avidly to immunostimulatory molecules
such as LPS, DNA, or interleukin (IL)-1β and promote their
activity in a synergistic fashion [38,39]. This feature can affect
the range of activities and potencies of HMGB1 preparations
(recombinant or purified from natural sources) since the
content of other components may vary.
In this construct on the function of HMGB1, the important
issue is not the contribution of any possible ‘contamination’ of
purified HMGB1 in in vitro experiments but rather the actual
function of the protein in vivo. We therefore would suggest
that HMGB1 functions in vivo to enhance inflammation by
binding PAMPs, DAMPs, and cytokines to promote dual-
receptor interactions that may be especially effective because
of their proximity. These receptors include RAGE, TLRs, β2-
integrin Mac-1, and possibly others. HMGB1-dependent
activation and recruitment of neutrophils have recently been
described to require a functional interplay between Mac-1
and RAGE [26]. Thus, HMGB1 may act synergistically with
other immunostimulatory molecules to modulate their
interaction with cells and amplify their activity because of their
physical association (Figure 1).
In its stimulation of the immune system, HMGB1 may differ
from conventional cytokines in another important aspect,
kinetics of expression, especially following in vivo induction
by LPS, a model used to study septic shock. Whereas
cytokines such as TNF-α and interferon (IFN)-γ are produced
rapidly following such stimulation, HMGB1 shows much more
sustained expression in the blood, with elevated levels
persisting long after the levels of the cytokines in the blood
have declined [40]. This prolonged expression likely reflects
the distinct manner in which HMGB1 is released from cells
and from endogenous sources as cells undergo stimulation
or stress in the pathological setting.
Available online http://arthritis-research.com/content/10/3/209
Table 1
Actions mediated by extracellular high-mobility group box protein 1 (HMGB1)
Target cells Biological actions of HMGB1
Dendritic cells Maturation and capacity to home to lymph nodes.
Monocytes/macrophages Potential proinflammatory cytokine production in collaboration with PAMP or DAMP molecules.
Induction of MMPs.
Promotes migration of monocytes.
Neutrophils Enhances chemotaxis.
Prevents apoptosis.
T lymphocytes Proliferation and polarization toward TH1.
B lymphocytes Potentiates activation by DNA-IgG complexes.
Epithelial cells Increased enterocyte permeability causing barrier dysfunction.
Bactericidal effects.
Platelets Expressed on cell surface by activated platelets.
Osteoclasts Enhances osteoclast formation and TNF release by direct binding to the TNF promoter.
Endothelial cells Proangiogenic.
Upregulation of adhesion molecules.
Smooth muscle cells Causes migration and proliferation.
Neurons Induces neurite outgrowth.
Astrocytes Proinflammatory activity, including chemotactic signals and MMP formation.
Induces glutamate release.




Tumor cells Enhances invasiveness.
MMP formation.
Strong HMGB1 overexpression.
DAMP, damage-associated molecular pattern; MMP, matrix metalloproteinase; PAMP, pathogen-associated molecular pattern; TNF, tumor necrosis
factor; VDJ, variable diversity joining.Release of HMGB1 during cell activation
To function as an alarmin, HMGB1 must transit from an
intracellular location to the extracellular space. As shown in
studies on macrophages and DCs, following cell activation,
HMGB1 undergoes post-translational modifications, inclu-
ding phosphorylation, acetylation, and methylation that modify
its charge. Once HMGB1 is modified, its interaction with
chromatin diminishes. Eventually, HMGB1 translocates to the
cytoplasm, where it can enter the endosomal compartment.
The exit of HMGB1 from the cell occurs via a non-conven-
tional secretory mechanism as cell activation proceeds [41-44].
In addition to LPS, proinflammatory mediators as well as TLR
ligands can trigger the release reaction. Thus, IFN-γ, IFN-α/β,
and nitric oxide (NO) can all induce externalization of
HMGB1. While TNF-α is often considered an inducer of
HMGB1 release, in a study [9] using an ELISPOT assay, its
activity was in fact limited. Among TLR ligands, triggering of
only some of these systems can induce translocation. Thus, in
contrast to the effects of ligands of TLR-3 and TLR-4,
stimulation of murine macrophages by CpG DNA fails to
induce translocation although this DNA can potently stimulate
cytokine release. While the basis for these differences is not
clear, the effect may result from the downstream pathways
stimulated. Both TLR-3 and TLR-4 involve the TRIF (TIR-
domain-containing adapter-inducing IFN-β) pathway whereas
TLR-9 does not [45,46].
Release of HMGB1 during cell death
In models on HMGB1 behavior of HMGB1 during cell death,
HMGB1 release generally has been considered a feature of
necrosis and not apoptosis. This tenet reflects the results of
original studies showing HMGB1 release from cells made
necrotic by freeze-thawing, heating, or ethanol [11,12]. Under
these conditions, HMGB1 translocation from the cell into the
external milieu occurs readily. Since HMGB1 is weakly
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Figure 1
The effects of high-mobility group box protein 1 (HMGB1) are dependent on complex formation with different ligands. The figure depicts a
possible, highly simplified scenario for the mechanisms for the various functions of HMGB1. During initiation of inflammation from infection, the
abundant presence of Toll-like receptor (TLR) ligands will induce signaling through TLR, resulting in strong, proinflammatory cytokine production.
The limited presence of HMGB1 at this stage will lead to weak signaling through receptor for advanced glycation endproducts (RAGE), thereby
inducing only limited cell migration, proliferation, and differentiation. During the expansion phase of inflammation, an increased concentration of
HMGB1, released from both activated and dead cells, occurs at the same time that TLR ligands are still present. Immune complexes formed
between HMGB1 and TLR ligands can induce signaling through RAGE and TLR receptors in close proximity to each other. This signaling can
increase and possibly prolong cytokine production as well as enhance cell migration, proliferation, and differentiation. During the
regeneration/repair phase of inflammation, TLR ligands decrease in amount while HMGB1 is still abundant. This situation will cause signaling
primarily through RAGE alone, leading to cell migration, proliferation, and differentiation while cytokine production diminishes. The illustration above
shows complex formation between HMGB1 and TLR ligands. It is also possible that endogenous, non-TLR signaling, danger molecules can form
complexes with HMGB1 and affect HMGB1 function in a similar way. HMGB1 can also enhance cytokine production when complexed to either
lipopolysaccharide or interleukin-1β. The scenario described for the regeneration and repair phase of inflammation would also pertain to the
function of HMGB1 during nerve sprouting, muscle cell regeneration, and other non-inflammatory circumstances in which the presence of HMGB1
has been described.adherent to chromatin, it can float away from the nucleus as
permeability barriers break down or the cell lyses. In contrast,
in these experiments, certain cell types such as HeLa cells
and fibroblasts induced to undergo apoptosis did not show
release; indeed, in these cells, HMGB1 appeared anchored
to the nucleus, implying structural modifications to enhance
the interactions of HMGB1 and chromatin [11,12].
Further studies with other cell lines, however, indicated that
the dichotomy in the behavior of HMGB1 is not as distinct as
originally proposed. Thus, Bell and colleagues [47] showed
that Jurkat cells made apoptotic by chemical inducers or
ultraviolet light demonstrated HMGB1 translocation by both
confocal microscopy and Western blotting. Although this
finding differs from previous observations, it is not unex-
pected since DNA and nucleosomes are released during late
apoptosis (a stage that can be called secondary necrosis)
and a host of other nuclear molecules are translocated into
blebs. The differences in the behavior of HMGB1 observed
may reflect the experimental systems used, including the cell
lines and inducers of apoptosis and necrosis.
While these issues require further study, understanding the
behavior of HMGB1 during apoptosis is relevant to the origin
of HMGB1 in disease states where extracellular HMGB1
occurs. Rather than implying inflammation or necrosis,
extracellular HMGB1 may point to apoptosis as well. In
general, HMGB1 release during primary necrosis exceeds
that which occurs during apoptosis, although the extent may
vary depending on the manner in which necrosis is induced.
The magnitude and functional consequences of HMGB1
release during secondary necrosis of apoptotic bodies are
topics that require much further investigation.
Role of HMGB1 in arthritis
As an alarmin, HMGB1 potentially plays an important role in a
wide variety of immunologically mediated conditions that range
from sepsis to autoimmunity. Of these diseases, rheumatoid
arthritis (RA) shows the clearest evidence for involvement of
HMGB1 in pathogenesis. Indeed, the pathology of the arthritic
joint would predict the abundant generation of extracellular
HMGB1 since chronic synovitis is characterized by macro-
phage activation, necrotic cell death (caused by activated
complement or ischemia), and apoptosis. In this setting, extra-
cellular HMGB1 release could perpetuate synovitis by
enhancing the expression of TNF-α, IL-1β, and IL-6 and other
proinflammatory factors by macrophages as well as their
action. Furthermore, cell membrane-expressed HMGB1 could
promote local tissue invasion by activating tissue plasminogen
activator and matrix metalloproteinases [48,49]. Since HMGB1
and TNF-α regulate osteoclastogenesis, HMGB1 may also
mediate structural damage by the pannus.
Experimental arthritis
Immunohistochemical staining of synovial tissue obtained
from mice and rats with collagen-induced arthritis (CIA) or
adjuvant-induced arthritis indicates a significant increase in
the extracellular expression of HMGB-1 and its appearance in
the cytoplasm of macrophage-like cells and vascular endo-
thelial cells in particular. In longitudinal studies of synovial
tissue from rats with CIA, the production of HMGB1, TNF-α,
and IL-β showed similar kinetics for production, without a
definite sequential order [49-54]. At early time points,
HMGB1 expression in this model is almost exclusively
restricted to the nuclear compartment while, as disease
proceeds, extranuclear HMGB1 becomes evident in resident
cells in the synovium (Figure 2).
While HMGB1, TNF-α, and IL-1 accumulate in the pannus
tissue in CIA, differences that may be relevant to their
pathogenetic role are also observed. Thus, in CIA, TNF-α
expression occurs in the lining layer as well as in sublining
areas in synovia, whereas HMGB1 and IL-1β expression
appears to be restricted to the sublining areas. HMGB1 and
IL-1β are also present in chondrocytes, which lack TNF-α
staining. Of note, intra-articular injection of recombinant
HMGB1 into murine knee joints incites an inflammatory
response that persists for at least 4 weeks [55], providing
evidence for a direct role of HMGB1 in synovitis.
Rheumatoid arthritis
Similar to findings in the animal models, aberrant extra-
nuclear HMGB1 expression in RA occurs in serum and
synovial tissue and in the synovial fluid [49,51,52] from
patients with RA. In particular, in synovial tissue, HMGB1
expression is prominent in vascular endothelial cells and
macrophages. Levels of HMGB1 in RA synovial fluid are
also higher than those from osteoarthritis [49-51]. Synovial
fluid macrophages exhibit increased expression of RAGE
and can be activated to release TNF-α, IL-1β, and IL-6 by
exposure to HMGB1 [51]. Since blockade by soluble
RAGE (sRAGE) inhibits the release of TNF-α from cultured
synovial fluid mononuclear cells, synovial monocyte/macro-
phages both can respond to inflammatory agents to trans-
locate HMGB1 and can be activated by HMGB1 to release
proinflammatory cytokines.
The role of HMGB1 in systemic lupus
erythematosus
Studies on patients with lupus support a role of HMGB1 in
disease manifestations. Thus, biopsies of skin of patients with
cutaneous lupus show an increased expression of this protein
in both the epidermis as well as dermal infiltrates in affected
skin. In these lesions, HMGB1 can be found in both the
cytoplasm of cells as well as in the extracellular space, with
extracellular localization being an important difference
between lesional and non-lesional skin. The origin of the
extracellular material cannot be determined from these
studies although it could arise from inflammatory cells as well
as keratinocytes. While these biopsies did not show necrotic
cells, apoptotic cells were present, representing another
potential source of the extracellular material. A direct role of
Available online http://arthritis-research.com/content/10/3/209
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that increased extracellular and cytoplasmic HMGB1 occurs
at the peak of lesions induced by experimental ultraviolet light
exposure [56,57].
HMGB1 may promote the pathogenesis of systemic lupus
erythematosus (SLE) by an entirely distinct mechanism. As
shown in studies of patients as well as murine models [58],
immune complexes containing DNA and RNA can drive the
production of IFN-α by plasmacytoid DCs. This stimulation
may involve both TLR as well as non-TLR signaling systems in
addition to the Fc receptor. In addition to their content of
nucleic acids, the stimulatory complexes contain HMGB1 and
can trigger responses via RAGE, which is one of the
receptors for HMGB1. Importantly, antibodies to RAGE can
block the in vitro induction of IFN-α. The effects of HMGB1 in
this setting may involve direct triggering of RAGE, transfer of
DNA into cells, and promotion of response by interaction with
TLR-9 [58].
A key question regarding the assembly of immune complexes
in SLE concerns the source of the constituent nuclear
molecules and the role of apoptosis in their expression. As
shown in both in vitro and in vivo studies, apoptosis yields
abundant amounts of extracellular DNA, the extent of which
may increase in SLE because of clearance defects. Since
HMGB1 can leave cells during apoptosis, the DNA and
HMGB1 in complexes may arise from the same cells during
apoptosis. Theoretically, HMGB1 could also bind to DNA in
preformed complexes although the kinetics and stochiometry
of the process are speculative. It is of interest, therefore, that
sera of patients with SLE as well as MRL-lpr/lpr mice have
increased amounts of HMGB1; these studies, however, did
not determine whether the HMGB1 was free or complexed
[59]. Of note, the development of autoantibodies to HMGB1
is a common feature in many autoimmune disorders, although
these antibodies may also be found in lower concentrations in
a majority of healthy blood donors. The functional relevance
of these antibodies is unknown at present [60].
HMGB1 and inflammatory muscle disease
Ulfgren and colleagues [61] reported in 2004 that HMGB1 is
present in an extranuclear location in muscle fibers from
patients with polymyositis and with dermatomyositis. In that
study, the muscle fibers expressing HMGB1 appeared
normal, without signs of degeneration or necrosis. In addition,
extranuclear HMGB1 could be detected in mononuclear cells
infiltrating the muscle tissue as well as in vascular endothelial
cells. Extracellular HMGB1 was also present in these sites; in
contrast, extranuclear HMGB1 could not be detected in
healthy muscle. Of note, treatment with high-dose predniso-
lone decreased the overall level of HMGB1 expression, an
effect that appeared to reflect a reduction in the number of
infiltrating inflammatory cells. Corticosteroid therapy, how-
ever, did not affect the HMGB1 expression in the muscle
fibers and in the vascular endothelial cells [61].
The findings on HMGB1 expression in inflammatory muscle
disease should be considered in light of reports that HMGB1
levels are increased in regenerating muscle recovering from
ischemic injury and that intramuscular injection of recombi-
nant HMGB1 induces both angiogenic and myogenic effects.
As shown in in vitro studies, differentiated myoblasts can
release HMGB1 that then acts as a chemotactic agent for
immature myogenic cells [62]. Others indicate that HMGB1
can suppress sarcomere contractibility by feline cardiac
myocytes  in vitro, pointing to a functional activity of the
released protein [63].
Together, these observations suggest that HMGB1 may play
a dual role during myositis. Thus, overexpression of extra-
cellular HMGB1 (likely from inflammatory cells) could pro-
mote inflammation and muscle fatigue, similar to its effect on
cardiac myocytes. Conversely, the extranuclear expression of
HMGB1 in stressed myocytes could represent a mechanism
to restore muscle function. Through induction of both new
vessel formation and migration and differentiation of
myogenic cells, locally released HMGB1 could counteract
the detrimental effects of the inflammatory mediators released
by the infiltrating mononuclear cells.
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Figure 2
High-mobility group box protein 1 (HMGB1) expression in collagen-
induced arthritis. The presence of cells expressing HMGB1 in the
invading pannus of collagen-induced arthritis is shown. In this
experiment, the section was stained for HMGB1 using affinity-purified
polyclonal rabbit anti-HMGB1 antibodies (BD Pharmingen, San Diego,
CA, USA) followed by biotin-labeled Fab2 fragments of a donkey anti-
rabbit antibody (Jackson ImmunoResearch Laboratories, Inc., West
Grove, PA, USA). The sections then were exposed to avidin-biotin-
horseradish peroxidase (Vectastain Elite, ABC kit; Vector Laboratories,
Burlingame, CA, USA), and color reaction was generated with
diaminobenzidine (DAB). Reproduced with permission from Nature
Insight 2002, 420:845-846 [http://www.nature.com/nature/insights/
6917.html]. Copyright 2002, Macmillan Publishers Ltd.HMGB1 and Sjögren syndrome
Immunohistochemical studies [64] have shown that, in tissue
from patients with Sjögen syndrome, extracellular and
cytoplasmic HMGB1 occurs in mononuclear infiltrates in
significantly higher levels than present in salivary glands from
both healthy individuals and patients with sicca syndrome. In
view of its activities in other settings, HMGB1 and Sjögren
syndrome could induce damage as part of a proinflammatory
loop with TNF-α and IL-1β, which are also expressed in
mononuclear infiltrates.
HMGB1 as a target of therapy
Rheumatology has benefited enormously from the research
on sepsis that defined the biology of TNF-α and provided the
scientific foundation for the development of TNF blockers as
a treatment for arthritis. History may repeat itself with
HMGB1 since this proinflammatory molecule, discovered as
a mediator of sepsis, may represent a novel therapeutic target
for arthritis. The concept of counteracting HMGB1 in
inflammatory diseases has so far been explored only in
preclinical models with strategies based on HMGB1
neutralization, inhibition of HMGB1 synthesis, and prevention
of extracellular HMGB1 release acting successfully in various
models of inflammatory and ischemic conditions. Therapies
related to autoimmune diseases will be discussed below.
Anti-HMGB1 antibodies
Short-term intervention with neutralizing polyclonal anti-
HMGB1 antibodies can prevent the progression of estab-
lished CIA in rodents [50], reducing clinical signs of arthritis,
weight loss, and joint damage. This treatment can also
attenuate TNF-α and IL-1β expression and histological signs
of inflammation. Despite results with polyclonal antibody,
however, monoclonal antibodies (mAbs) against HMGB1
have thus far shown limited or no effects. Indeed, using
individual anti-HMGB1 mAbs reacting with different epitopes,
we have been unable to improve murine CIA in a reproducible
manner (H. Erlandsson-Harris, U. Andersson, unpublished
data). To account for the lack of therapeutic activity of mAbs,
we can speculate that HMGB1 in vitro avidly may bind
different molecules, thereby preventing HMGB1-specific
mAbs from recognizing any given epitope of the HMGB1
molecule. In contrast, polyclonal antibodies reacting with
multiple epitopes on the whole molecule could circumvent
the problem resulting from occupancy of binding sites by
ligated determinants.
Although mAbs have not worked in arthritis models so far,
there is evidence that an mAb can improve the outcome in a
preclinical model of stroke. An interesting feature of this
antibody relates to its specificity, which is directed to the end
part of the repetitive C-terminal tail of the molecule [65]. To
our knowledge, this is a unique specificity that has not been
explored in other studies. Since the acidic C-terminal part can
make extensive intramolecular contacts with the DNA-binding
surfaces of both HMG boxes, this feature may make the tail
more accessible for antibody recognition; the mAb could also
prevent the interaction of other molecules with the DNA-
binding boxes. The efficacy of anti-HMGB1 treatment in
ischemia is supported by evidence on the benefits of
HMGB1 mRNA downregulation in the brain prior to vessel
ligation [66].
HMGB1 A box protein
Structure-function analysis has demonstrated that the DNA-
binding B box domain mediates the proinflammatory effects
of HMGB1, while the DNA-binding A box is an anti-
inflammatory molecule that inhibits these activities mediated
by full-length HMGB1 protein [67]. In a study of CIA,
systemic administration of A box protein reduced mean
arthritis score, disease-induced weight loss, and histologic
severity [50] in mice and rats. Furthermore, immunohisto-
chemistry showed that, compared with findings in vehicle-
treated mice, synovial IL-1β expression and articular cartilage
destruction were significantly reduced in animals treated with
active A box protein compound. A box protein therapy also
confers significant clinical protection in other experimental
inflammatory conditions, including Gram-negative sepsis,
endotoxemia, and pneumonia [67].
Soluble RAGE and anti-RAGE antibodies
RAGE is a cell-bound receptor of the immunoglobulin
superfamily which is activated by a variety of proinflammatory
ligands, including HMGB1, advanced glycated endproducts,
members of S100 proteins, and amyloid beta-peptide [68].
RAGE has a secretory splice isoform, sRAGE, which lacks
the transmembrane domain and circulates in plasma. By
competing with cell surface RAGE for ligand binding, sRAGE
may act as a decoy receptor by removing circulating RAGE
ligands. Consistent with the role of RAGE as an HMGB1
receptor, treatment with sRAGE protein can ameliorate both
inflammation and structural damage in CIA [47]. Anti-RAGE-
specific mAb can also block an experimental model of sepsis
[69], supporting this pathway as a target for therapies.
Thrombomodulin
Thrombomodulin is an endothelial anticoagulant cofactor that
promotes thrombin-mediated formation of activated protein
C. The N-terminal lectin-like domain of thrombomodulin is not
functionally involved in the coagulation system but binds to
HMGB1 and neutralizes its extracellular proinflammatory
activity [70]. Therapy based on truncated thrombomodulin
can significantly ameliorate several forms of experimental
arthritis [71].
Nuclear HMGB1 retention
In addition to inhibiting the action of extracellular HMGB1,
therapeutic strategies to promote intranuclear retention of
HMGB1 have been explored. Among chemical approaches,
covalent DNA adducts generated by the platinating antitumor
drug oxaliplatin can sequester nuclear HMGB1, since
HMGB1 avidly binds to sites of distorted DNA. Of interest,
Available online http://arthritis-research.com/content/10/3/209
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inflammation in murine CIA as long as extracellular HMGB1
expression is low due to therapy [53]. When oxaliplatin
treatment is interrupted in this model, rebound of disease
occurs, with clinical flare coinciding with massive extracellular
HMGB1 release.
Other heavy metals may also affect HMGB1 release. Thus, in
vitro experiments have shown that gold salts can inhibit the
nuclear export of HMGB1 in activated macrophages [72].
The effect of gold appears to be specific for certain
mediators since the release of HMGB1, NO, and IFN-β was
inhibited by gold sodium thiomalate at pharmacologically
relevant doses, whereas TNF release was not affected. These
results suggest a new mechanism for the antirheumatic
effects of gold salts in RA and the potential of drugs that
interfere with intracellular HMGB1 transport mechanisms as
novel agents to treat RA.
The cholinergic anti-inflammatory pathway
In experimental disease models, the cholinergic anti-inflam-
matory pathway, a vagus nerve-dependent mechanism,
inhibits HMGB1 release [73]. A study of patients with RA
showed an association of decreased vagus nerve activity with
increased HMGB1 serum levels [74]. The study did not allow
a determination of causality but supports future attempts to
stimulate the vagus nerve to decrease HMGB1 levels and
ameliorate inflammation. Of note, acetylcholine in vagus nerve
synapses mediates important anti-inflammatory effects via α7
nicotinic acetylcholine receptors (α7nAcR) present on the
surface of macrophages and other cells. Selective agonists to
α7nAcR are under development to treat inflammatory
conditions [75].
Effects on HMGB1 expression in rheumatoid arthritis
synovitis in response to established therapy
In addition to new agents, existing therapy may affect
HMGB1 expression. Thus, intra-articular corticosteroid injec-
tions in RA patients can downregulate extranuclear expres-
sion of HMGB1 as well as synovial TNF-α and IL-1β. In
contrast, synovial HMGB1 expression was not consistently
influenced by TNF blocking therapy with infliximab in nine
studied RA patients [76]. These findings could suggest that
HMGB1 acts upstream of TNF in the rheumatoid synovial
inflammation.
Conclusion
As an alarmin, HMGB1 can play a pivotal role in the
pathogenesis of a wide variety of inflammatory conditions and
may present a new target of therapy for RA and related
rheumatic diseases. Future studies will define the pathways
for HMGB1 release in disease, elucidate the most effective
strategies for blocking the effect of this mediator, and
determine the nature of any side effects that develop when
levels of HMGB1 are reduced. Whatever the outcomes of
these experiments, the study of HMGB1 should provide an
important new perspective on the dynamics of these
molecules inside the cell and the diversity of activities that
these molecules display once they are outside.
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